LEADER 04270nam 2200685Ia 450 001 9910451253703321 005 20210615022618.0 010 $a1-282-19482-8 010 $a9786612194825 010 $a3-11-019970-X 024 7 $a10.1515/9783110199703 035 $a(CKB)1000000000335184 035 $a(EBL)280159 035 $a(OCoLC)476023249 035 $a(SSID)ssj0000229106 035 $a(PQKBManifestationID)11188415 035 $a(PQKBTitleCode)TC0000229106 035 $a(PQKBWorkID)10155935 035 $a(PQKB)10675981 035 $a(MiAaPQ)EBC280159 035 $a(WaSeSS)Ind00014110 035 $a(DE-B1597)19797 035 $a(OCoLC)979954955 035 $a(DE-B1597)9783110199703 035 $a(Au-PeEL)EBL280159 035 $a(CaPaEBR)ebr10154770 035 $a(CaONFJC)MIL219482 035 $a(OCoLC)228144658 035 $a(EXLCZ)991000000000335184 100 $a20050902d2005 uy 0 101 0 $aeng 135 $aurnn#---|u||u 181 $ctxt 182 $cc 183 $acr 200 00$aProjective varieties with unexpected properties$b[electronic resource] $ea volume in memory of Giuseppe Veronese : proceedings of the international conference "Varieties with Unexpected Properties," Siena, Italy, June 8-13, 2004 /$fedited by Ciro Ciliberto ... [et al.] 210 $aBerlin ;$aNew York $cWalter de Gruyter$d2005 215 $a1 online resource (400 p.) 225 0 $aDe Gruyter Proceedings in Mathematics 300 $aDescription based upon print version of record. 311 0 $a3-11-018160-6 327 $tFront matter --$tContents --$tCharacterization of Veronese varieties via projection in Grassmannians --$tBirational geometry of defective varieties --$tFano three-folds as hyperplane sections --$tTriple points imposing triple divisors and the defective hierarchy --$tM15 is rationally connected --$tCodimension one decompositions and Chow varieties --$tHigher secant varieties of Segre-Veronese varieties --$tAn appendix to a paper of Catalisano, Geramita, Gimigliano: The Hilbert function of generic sets of 2-fat points in P1 × P1 --$tThe 3-cuspidal quartic and braid monodromy of degree 4 coverings --$tOn the classification of defective three-folds --$tMatching conditions for degenerating plane curves and applications --$tNegative curves on very general blow-ups of P2 --$tLinear congruences and hyperbolic systems of conservation laws --$tA note on the very ampleness of complete linear systems on blowings-up of P3 --$tPhylogenetic algebraic geometry --$tSome results on fat points whose support is a complete intersection minus a point --$tThe (unexpected) importance of knowing ? --$tHilbert functions of Gorenstein algebras associated to a pencil of forms --$tVarieties of reductions for gln --$tBirational geometry of rationally connected manifolds via quasi-lines --$tOn the discriminant of spanned line bundles --$tMultisecant lines to projective varieties --$tCycle map on Hilbert schemes of nodal curves --$tBack matter 330 $aThis volume contains refereed papers related to the lectures and talks given at a conference held in Siena (Italy) in June 2004. Also included are research papers that grew out of discussions among the participants and their collaborators. All the papers are research papers, but some of them also contain expository sections which aim to update the state of the art on the classical subject of special projective varieties and their applications and new trends like phylogenetic algebraic geometry. The topic of secant varieties and the classification of defective varieties is central and ubiquitous 410 3$aDe Gruyter Proceedings in Mathematics 606 $aAlgebraic varieties$vCongresses 606 $aGeometry, Projective$vCongresses 608 $aElectronic books. 615 0$aAlgebraic varieties 615 0$aGeometry, Projective 676 $a516.3/53 686 $aSD 2004$2rvk 701 $aVeronese$b Giuseppe$f1854-1917.$056376 701 $aCiliberto$b C$g(Ciro),$f1950-$042512 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910451253703321 996 $aProjective varieties with unexpected properties$92489233 997 $aUNINA LEADER 05061nam 22006855 450 001 9910377840203321 005 20250609110753.0 010 $a3-030-28400-X 024 7 $a10.1007/978-3-030-28400-8 035 $a(CKB)4100000010236924 035 $a(DE-He213)978-3-030-28400-8 035 $a(MiAaPQ)EBC6038297 035 $a(PPN)242976603 035 $a(MiAaPQ)EBC6038278 035 $a(EXLCZ)994100000010236924 100 $a20200207d2019 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHCV: The Journey from Discovery to a Cure $eVolume II /$fedited by Michael J. Sofia 205 $a1st ed. 2019. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019. 215 $a1 online resource (VIII, 500 p. 50 illus., 20 illus. in color.) 225 1 $aTopics in Medicinal Chemistry,$x1862-2461 ;$v32 311 08$a3-030-28399-2 327 $aNS5A as a target for HCV Drug Discovery -- The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex -- The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen HarvoniŽ -- The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens EpclusaŽ and VoseviŽ -- Discovery of Elbasvir -- HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments -- Evolution of HCV NS4B Inhibitors -- The Evolution of Clinical Trials for Hepatitis C -- The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, HarvoniŽ) -- The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, EpclusaŽ) -- The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, VoseviŽ) -- Clinical Development of Viekira Pak to Mavyret -- Development of ZEPATIERŽ -- Real world effectiveness of DAA therapies -- The Benefit of Direct-Acting Antiviral HCV Cure Therapies -- Cure and Control: What Will It Take to Eliminate HCV? -- Perspectives on HCV Cure. 330 $aHepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I". 410 0$aTopics in Medicinal Chemistry,$x1862-2461 ;$v32 606 $aPharmaceutical chemistry 606 $aVirology 606 $aClinical biochemistry 606 $aBioorganic chemistry 606 $aPharmaceutical technology 606 $aMedicinal Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C28000 606 $aVirology$3https://scigraph.springernature.com/ontologies/product-market-codes/B22003 606 $aMedical Biochemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/H35005 606 $aBioorganic Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C19010 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 615 0$aPharmaceutical chemistry. 615 0$aVirology. 615 0$aClinical biochemistry. 615 0$aBioorganic chemistry. 615 0$aPharmaceutical technology. 615 14$aMedicinal Chemistry. 615 24$aVirology. 615 24$aMedical Biochemistry. 615 24$aBioorganic Chemistry. 615 24$aPharmaceutical Sciences/Technology. 676 $a616.362306 676 $a616.3623 702 $aSofia$b Michael J$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910377840203321 996 $aHCV: The Journey from Discovery to a Cure$91732378 997 $aUNINA